Analyze how new policies affect prescription drug availability and launch timings in the US compared to other OECD nations, with insights from RAND’s comprehensive report.
Discover the latest analysis on how the IRA may cause delays in drug launches, reduce subsequent indications, and limit evidence generation.
Explore how the IRA influences drug launch analytics, leading to delays, fewer indications, and reduced evidence generation in the pharmaceutical industry.
Understand the challenges and opportunities decentralized clinical trials present for small to midsize biotechnology and biopharmaceutical companies, and how to effectively navigate them for successful outcomes.
Explore key considerations and strategies for small to midsize biotechnology and biopharmaceutical companies navigating decentralized clinical trials to enhance efficiency and patient outcomes.
Delve into our comprehensive analysis of US cancer drug launch prices and their clinical efficacy, uncovering trends and insights essential for pharmaceutical success.
Explore the trends in US cancer drug launch prices and their clinical efficacy from 2008 to 2022, providing valuable insights for optimizing drug launch analytics in the pharmaceutical industry.
Explore the trends in US cancer drug launch prices and their clinical efficacy from 2008 to 2022, providing valuable insights for optimizing drug launch analytics in the pharmaceutical industry.
Explore how Foundation Medicine provides top-tier biopharmaceutical services and cutting-edge cancer genomics insights, connecting physicians, patients, and partners for advanced healthcare solutions.
Discover how human data science enhances disease prediction, identifies new therapeutic targets, and optimizes patient populations for next-generation pharmaceuticals.
Discover how AstraZeneca is at the forefront of biopharmaceutical services, driving global health advancements through innovative research and development.
Explore the latest trends in Biopharmaceutical Services through the lens of Bristol Myers Squibb, a global leader in developing and delivering innovative medicines.
Discover key insights from our 2023-2024 Drug Launch Analytics Report, focusing on pricing strategies and access trends in pharmaceutical drug approvals.
Discover critical insights from the 2023-2024 drug approvals in our comprehensive Drug Launch Analytics report, focusing on launch pricing and access strategies.
Explore how drug launch analytics reveal disparities in cancer drug pricing between the US and Europe, and uncover the policy implications driving these trends.
Analyze the disparities in cancer drug pricing and clinical benefits between the US and Europe, exploring policy implications and market trends post-approval.